Onconetix, INC Form 4 insider transactions

Onconetix, Inc. announced that its pending acquisition target, Realbotix LLC, has secured an agreement to feature its humanoid robot in an Emmy Award-winning streaming series, signaling broader market adoption.

Onconetix's subsidiary Realbotix is launching a UK pilot program using humanoid robots to combat social isolation among the elderly, partnering with Bloom Procurement Services.

Realbotix, the pending acquisition target of Onconetix, has launched an AI-powered teachers assistant and humanoid robot pilot program in a New York school district.

HRT Financial LP reports significant transactions in Onconetix, Inc. Class A Shares, acquiring 49,710 shares.

HRT FINANCIAL LP reports significant transactions in Onconetix, Inc. Class A Shares.

HRT Financial LP acquired 166,904 shares of Onconetix, Inc. across two transactions on April 14 and April 15, 2026.

Onconetix, Inc. highlights the launch of Realbotix's Vinci AI Vision System, enabling humanoid robots to recognize individuals and recall conversations, following Onconetix's pending acquisition of Realbotix LLC.

Onconetix reports that its acquisition target, Realbotix, expects to deliver 19 humanoid robots between March and May 2026.

Onconetix appoints David White as CEO and Sammy Dorf to its Board, strengthening leadership for the pending acquisition of AI-powered humanoid robotics developer Realbotix LLC.

Onconetix draws attention to its acquisition target Realbotix's humanoid robot being featured as a live connected endpoint in Ericsson's world-first pre-standard 6G over-the-air trial.

Onconetix, Inc. announced a definitive share exchange agreement to acquire Realbotix, LLC, an AI-powered humanoid robotics company, in an all-stock transaction.

Onconetix, Inc. director Andrew John Oakley's restricted stock awards were modified and new awards granted, with vesting extended to August 2026.

Onconetix director Simon Tarsh received a new restricted stock award and had an existing award's vesting terms extended, following a 1-for-85 reverse stock split.

Onconetix director Thomas Meier's restricted stock awards were modified and granted, extending vesting periods and increasing his beneficial ownership.

Onconetix Director Timothy R. Ramdeen's restricted stock awards were modified and granted, extending vesting periods and reflecting a recent reverse stock split.

Altos Venture AG, a 10% owner and director of Onconetix, Inc., acquired an additional 241,514 shares of common stock on July 14, 2025, pursuant to a make-whole provision from a prior subscription agreement, following two significant reverse stock splits by the issuer.

Director Andrew John Oakley reports acquisition of 1,709 restricted stock units in Onconetix, Inc.

Ralph Schiess, Interim CEO and CSO of Onconetix, Inc., reports acquiring and disposing of common stock on December 20, 2024.

Christian Bruhlmann, Chief Strategy Officer of Onconetix, Inc., reports acquiring and disposing of common stock on December 20, 2024.

Director Simon Tarsh reports acquisition of restricted stock and disposal of common stock in Onconetix, Inc.

Director Ajit Singh acquired 3,318 shares of Onconetix common stock through a restricted stock award.

Director James Sapirstein reports acquisition of restricted stock award and disposal of common stock.

Director Timothy R. Ramdeen reports acquisition of restricted stock and disposal of common stock.

Director Thomas Meier acquired 3,318 shares of Onconetix, Inc. common stock through a restricted stock award.

Christian Bruhlmann, Chief Strategy Officer of Onconetix, Inc., reports the conversion of Series B preferred stock into common stock.

Ralph Schiess, Interim CEO & CSO of Onconetix, Inc., reports the conversion of Series B preferred stock into common stock.